Medtronic plc Stock
Medtronic plc Stock
Pros and Cons of Medtronic plc in the next few years
Pros
Cons
Performance of Medtronic plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medtronic plc | -0.050% | 1.782% | 2.669% | -3.753% | -8.094% | -2.078% | -31.079% |
| Dexcom Inc. | 0.550% | 1.381% | 13.622% | 11.941% | 28.053% | -33.224% | -33.182% |
| Baxter International | 0.680% | 5.026% | 18.981% | 17.950% | 46.207% | -39.848% | -62.571% |
| Idexx Laboratories Inc. | -0.510% | 4.725% | 1.622% | -9.032% | -13.171% | 9.894% | -12.813% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at Medtronic's financials, the company appears to be a strong player in the Healthcare Equipment & Supplies sector. Over the years, Medtronic has demonstrated relatively stable financial performance, which is a desirable attribute for a healthcare company. However, more in-depth analysis is needed to better understand the pros and cons of its financial situation.
Revenue Growth: Medtronic's total revenue has experienced consistent growth over the last three years as seen in the yearly income statements. In 2020, the company recorded total revenue of $28.913 billion which increased to $30.117 billion in 2021, and further to $31.686 billion in 2022.
Increasing Gross Profit: Medtronic has seen a rise in its gross profit, from $19.489 billion in 2020 to $19.634 billion in 2021, and eventually $21.541 billion in 2022. This implies that the company is becoming more efficient in its manufacturing and supply chain activities, which is a good sign for potential investors.
Comments
News
I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026
Shares of Medtronic (NYSE: MDT), one of the world's largest medical device makers, have declined by more than 30% over the past five years. Higher costs, supply chain bottlenecks, quality control
Pediatrix Medical Group Q2 Earnings Call Highlights
Key Points
- Interested in Pediatrix Medical Group, Inc.? Here are five stocks we like better.
- Pediatrix reported Q2 adjusted EBITDA of $76 million and reaffirmed its full-year outlook of $280
Proto Labs Q2 Earnings Call Highlights
Key Points
- Interested in Proto Labs, Inc.? Here are five stocks we like better.
- Record revenue and stronger profitability: Proto Labs reported Q2 revenue of $149.3 million, up 10.2% year over